CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


ioveraºWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2861 ioveraº sham Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D010149 Pain, Postoperative NIH 0.71

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Multicenter, Double-blind, Randomized, Sham-controlled Study Assessing Opioid Utilization, Postoperative Pain and Function in Subjects Undergoing Total Knee Arthroplasty Treated With Presurgical Iovera®° or Sham Iovera®° Cryoneurolysis and Postsurgical Multimodal Pain Regimen

Primary objective: The primary objective of this study is to evaluate either a) the postsurgical total opioid consumption or b) postsurgical pain control after presurgical iovera° treatment plus EXPAREL® and standardized multimodal therapy compared with presurgical sham iovera° treatment plus EXPAREL and standardized multimodal therapy in subjects undergoing primary unilateral total knee arthroplasty (TKA). A single primary objective, either a or b, will be declared by an unblinded Independent Review Committee (IRC) in an interim analysis after 30 randomized and treated subjects complete the Day 42 assessments. The primary objective not selected will be placed in the secondary objectives category. Secondary objectives: The secondary objectives of this study are to compare postsurgical pain control or postsurgical total opioid consumption (whichever is not chosen as the primary objective), opioid-free status, physical function, sleep quality, and safety of presurgical iovera° treatment plus EXPAREL and standardized multimodal therapy with presurgical sham iovera° treatment plus EXPAREL and standardized multimodal therapy in subjects undergoing primary unilateral TKA

NCT04191031 Post-Operative Pain Management Device: ioveraº Device: ioveraº sham
MeSH:Pain, Postoperative

Primary Outcomes

Measure: Total opioid consumption in oral morphine equivalent dose from TKA (Day 1) to Day 42 (6 weeks post-TKA)

Time: Day 1 to Day 42

Secondary Outcomes

Description: NRS scale is 0 to 10 with 0 being no pain and 10 being the worst pain

Measure: The area under the curve (AUC) of the Numeric Rating Scale (NRS) "worst pain" intensity scores from TKA (Day 1) to Day 42 (6 weeks post-TKA)

Time: Day 1 to Day 42

Description: NRS scale is 0 to 10 with 0 being no pain and 10 being the worst pain

Measure: Numeric Rating Scale (NRS) pain intensity scores "right now" at Day 15, 30, 42, and Day 90

Time: Day 15 to Day 90

Description: NRS scale is 0 to 10 with 0 being no pain and 10 being the worst pain

Measure: Numeric Rating Scale (NRS) pain intensity scores "average pain" at Day 4 to Day 42

Time: Day 4 to Day 42

Measure: Total opioid consumption in oral morphine equivalents from TKA-Day 15, TKA-Day 30, TKA-Day 42, and TKA-Day 90

Time: Day 1 to Day 90


No related HPO nodes (Using clinical trials)